The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
|Articles|January 26, 2022
Aposave Rebrands to Abacus Medicine Pharma Services
Advertisement
Abacus Medicine Pharma Services (Farnborough, UK) is the new name for the healthcare and pharma services company previously known as Aposave.
The rebrand reflects the company’s plans to access to the US and Chinese markets.
Through its parallel distribution division, the organization has been providing access to pharmaceutical products and healthcare to Europeans for almost 20 years. In order to establish a global footprint, the group — which has three service lines: Clinical Trial Solutions, Commercial Partnerships and Unlicensed Medicines — established a full healthcare and pharma services division with commercial headquarters in the UK in 2020. Today, it has companies in the US, UK, Denmark, Hong Kong and The Netherlands.
“We made an excellent start as Aposave and now as Abacus Medicine Pharma Services we plan to make significant strides forward,” commented managing director Simon Estcourt.
Advertisement
Related to this article
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In this week's Pharma Pulse, Arkansas independent pharmacies bring an underpayment suit against Express Scripts, Novo Nordisk taps Anthropic for AI-driven drug discovery, and Sanofi, UCB and Opella join AstraZeneca on a supply chain heat decarbonization program.
DSCSA data exchange has matured into daily operations, but the coming NDC-12 shift and a national licensure standard add new work streams before old ones are fully settled.
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
An FTC settlement moved one PBM aggregator onshore, but manufacturers still lack contract-level clarity on what affiliated fees actually buy.
Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
White House Extends MFN Pricing to Every State Medicaid Program
2
Pharma Pulse: Independent Pharmacies Sue Express Scripts, Novo Taps Anthropic, Pharma Joins Clean Heat
3
The PBM Entity No Pharmaceutical Company Directly Contracted With
4
How Rebate Timing Distorts a Pharmacy's 340B Books
5